We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Incyte (INCY - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Incyte is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Incyte is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for INCY's full-year earnings has moved 1.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, INCY has returned 2.1% so far this year. Meanwhile, the Medical sector has returned an average of -4.5% on a year-to-date basis. This means that Incyte is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Atara Biotherapeutics (ATRA - Free Report) . The stock is up 16.8% year-to-date.
The consensus estimate for Atara Biotherapeutics' current year EPS has increased 20.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Incyte belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual stocks and currently sits at #63 in the Zacks Industry Rank. Stocks in this group have lost about 14% so far this year, so INCY is performing better this group in terms of year-to-date returns. Atara Biotherapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Incyte and Atara Biotherapeutics as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Incyte (INCY - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Incyte is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Incyte is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for INCY's full-year earnings has moved 1.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, INCY has returned 2.1% so far this year. Meanwhile, the Medical sector has returned an average of -4.5% on a year-to-date basis. This means that Incyte is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Atara Biotherapeutics (ATRA - Free Report) . The stock is up 16.8% year-to-date.
The consensus estimate for Atara Biotherapeutics' current year EPS has increased 20.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Incyte belongs to the Medical - Biomedical and Genetics industry, a group that includes 513 individual stocks and currently sits at #63 in the Zacks Industry Rank. Stocks in this group have lost about 14% so far this year, so INCY is performing better this group in terms of year-to-date returns. Atara Biotherapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Incyte and Atara Biotherapeutics as they could maintain their solid performance.